Trials / Sponsors / HI-Bio, A Biogen Company
HI-Bio, A Biogen Company
Industry · 5 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Active Not Recruiting | A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Lupus Nephritis | Phase 1 | 2023-11-01 |
| Completed | A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers Immune System Diseases, Autoimmunity | Phase 1 | 2023-07-06 |
| Completed | Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephr Immunoglobulin A (IgA) Nephropathy | Phase 2 | 2021-08-31 |
| Completed | Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) Glomerulonephritis, Membranous Nephropathy, antiPLA2R Positive | Phase 2 | 2021-01-20 |
| Completed | Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) Glomerulonephritis, Membranous, antiPLA2R Positive | Phase 1 / Phase 2 | 2019-10-15 |